Thermo Fisher Scientific reported third-quarter revenue of $12.14 billion, up 9%, and higher earnings on both reported and adjusted bases. The results announced on 21 October 2026 cover the quarter ended 26 September, not the calendar quarter ending 30 September.
GAAP diluted earnings per share rose 9% to $4.64. Adjusted EPS increased 15% to $6.68. The two figures answer different questions: the first follows US accounting rules, while the second removes items listed in the company’s reconciliation.
Results at a glance
| Measure | Result or outlook |
|---|---|
| Reporting period | Three months ended 26 September 2026; comparator ended 27 September 2025. Source |
| Revenue | $12.137 billion versus $11.122 billion; growth rounded to 9%. Source |
| Organic revenue growth — non-GAAP | 6%; excludes acquisition/divestiture and currency-translation effects. Source |
| GAAP diluted EPS | $4.64 versus $4.27. Source |
| Adjusted EPS — non-GAAP | $6.68; up 15% as reported by the issuer. Source |
| GAAP operating income and margin | $2.263 billion; 18.6% margin versus 17.4%. Source |
| Adjusted operating income and margin — non-GAAP | $2.968 billion; 24.5% margin versus 23.3%. Source |
How to read the gap between earnings measures
Operating margin is operating income divided by revenue. On the reported basis, $2.263 billion divided by $12.137 billion is approximately 18.6%. The adjusted margin uses a different numerator because it excludes specified costs; it must not be presented as the GAAP margin.
Thermo Fisher’s reconciliation identifies acquisition-related intangible-asset amortization, restructuring and other costs among the adjustments. These exclusions can help readers compare periods, but they do not make the underlying costs disappear. The reported and adjusted measures should therefore remain side by side.
Organic growth likewise differs from total sales growth. The official quarterly schedule reconciles 9% reported revenue growth with acquisition/divestiture and currency effects to arrive at 6% organic growth. It is a company-defined non-GAAP measure, not a second revenue total.
What is not established by this release
The release said updated full-year guidance would be provided during the earnings call. This report does not invent a revised annual range or treat management’s general optimism as a numerical forecast. Later official guidance should be checked against its own dated record.
For separate medical-technology earnings coverage, read CapKet’s Intuitive Surgical report. The companies and their accounting adjustments are different; this is context, not a like-for-like valuation comparison.
Official sources and verification scope
Issuer’s 21 October 2026 results release · Official financial statements and reconciliation
Source records observed at 2026-10-21T19:15:14.481Z. The linked records are issued by the same company; alternate release and PDF formats are not independent corroboration. This is an AI-assisted primary-document check, not independent human editorial approval. All monetary figures are US dollars; EPS means earnings per share.
Recorded source observation: . This is a source-check timestamp, not a market quote or a new article update.